Drug Type Biosimilar, Monoclonal antibody |
Synonyms Denosumab Biosimilar (Xentria, Inc.), 地舒单抗生物类似药(Xentria, Inc.), MAB-22 |
Target |
Mechanism RANKL inhibitors(Tumor necrosis factor ligand superfamily member 11 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization Xentria, Inc.Startup |
Active Organization Xentria, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoporosis | Phase 3 | - | Xentria, Inc.Startup | 01 Oct 2025 |
Neoplasms | Phase 1 | US | Xentria, Inc.Startup | - |